Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Cluster analysis and display of genome-wide expression patterns

Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

Epidermal growth factor-related peptides and their receptors in human malignancies

Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

Giles, K. M., Kalinowski, F. C., Candy, P. A., Epis, M. R., Zhang, P. M., Redfern, A. D., Stuart, L. M., Goodall, G. J., & Leedman, P. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0170 · Cited by 155

Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer

Javle, M. M., Gibbs, J. F., Iwata, K. K., Pak, Y., Rutledge, P., Yu, J., Black, J. D., Tan, D., & Khoury, T. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9540-3 · Cited by 154

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

Wilson, C., Ye, X., Pham, T., Lin, E., Chan, S., McNamara, E., Neve, R. M., Belmont, L., Koeppen, H., Yauch, R. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1009 · Cited by 150

Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs

Ahmad, A., Maitah, M. Y., Ginnebaugh, K. R., Li, Y., Bao, B., Gadgeel, S. M., & Sarkar, F. H. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-77 · Cited by 146

Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung

Prudkin, L., Liu, D. D., Ozburn, N. C., Sun, M., Behrens, C., Tang, X., Brown, K. C., Bekele, B. N., Moran, C. A., & Wistuba, I. I. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.19 · Cited by 145

Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling

Yi, Y., Zeng, S., Wang, Z., Wu, M., Ma, Y., Ye, X., Zhang, B., & Liu, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.12.021 · Cited by 145

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

Bruzzese, F., Leone, A., Rocco, M., Carbone, C., Piro, G., Caraglia, M., Gennaro, E. D., & Budillon, A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22574 · Cited by 142

Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas

Dauphin, M., Barbe, C., Lemaire, S., Nawrocki‐Raby, B., Lagonotte, E., Delépine, G., Birembaut, P. L., Gilles, C., & Polette, M. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.03.011 · Cited by 138

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 137

Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells

Sun, Y., Daemen, A., Hatzivassiliou, G., Arnott, D. P., WILSON, C. A., Zhuang, G., Gao, M., Liu, P. J., Boudreau, A., Johnson, L., et al. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-20 · Cited by 134

Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines

Coldren, C. D., Helfrich, B. A., Witta, S. E., Sugita, M., Lapadat, R., Zeng, C., Barón, A., Franklin, W. A., Hirsch, F. R., Geraci, M. W., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0095 · Cited by 136

E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression

Lau, M.-T., Klausen, C., & Leung, P. C. K. (2011) · Oncogene · doi:10.1038/onc.2011.6 · Cited by 132

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

Zhu, J., Zhong, W., Zhang, G.-C., Li, R., Zhang, X., Guo, A., Zhang, Y.-F., An, S., Mok, T. S. K., & Wu, Y.-L. L. C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.064 · Cited by 129

N-Cadherin Expression Is Associated with Acquisition of EMT Phenotype and with Enhanced Invasion in Erlotinib-Resistant Lung Cancer Cell Lines

Zhang, X., Liu, G., Kang, Y., Dong, Z., Qian, Q., & Ma, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057692 · Cited by 129

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Helfrich, B. A., Raben, D., Varella‐Garcia, M., Gustafson, D., Chan, D. C. F., Bemis, L., Coldren, C. D., Barón, A. E., Zeng, C., Franklin, W. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0760 · Cited by 126

The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors

Izumchenko, E., Chang, X., Michailidi, C., Kagohara, L. T., Ravi, R. K., Paz, K., Brait, M., Hoque, M. O., Ling, S., Bedi, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0110 · Cited by 124

Epithelial–mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis

Lou, Y., Preobrazhenska, O., Keller, U. A. D., Sutcliffe, M., Barclay, L., McDonald, P. C., Roskelley, C. D., Overall, C. M., & Dedhar, S. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21658 · Cited by 131

Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation

Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124

TGF-β: An emerging player in drug resistance

Brunen, D., Willems, S., Kellner, U., Midgley, R., Simon, I., & Bernards, R. (2013) · Cell Cycle · doi:10.4161/cc.26034 · Cited by 124

Cancer stem cells and chemoradiation resistance

Ishii, H., Iwatsuki, M., Ieta, K., Ohta, D., Haraguchi, N., Mimori, K., & Mori, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00914.x · Cited by 123

SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer

Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, M., Papaccio, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3319 · Cited by 122

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

Nagai, T., Arao, T., Furuta, K., Sakai, K., Kudo, K., Kaneda, H., Tamura, D., Aomatsu, K., Kimura, H., Fujita, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0544 · Cited by 120

The rejuvenated scenario of epithelial–mesenchymal transition (EMT) and cancer metastasis

Meng, F., & Wu, G. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9379-3 · Cited by 123

Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt

Yamasaki, F., Johansen, M. J., Zhang, D., Krishnamurthy, S., Felix, E. A., Bartholomeusz, C., Aguilar, R. J., Kurisu, K., Mills, G. B., Hortobágyi, G. N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3020 · Cited by 118

New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors

Chen, L. F., Cohen, E. E. W., & Grandis, J. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2318 · Cited by 120

The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer Cells

Milligan, S. A., Burke, P., Coleman, D. T., Bigelow, R. L. H., Steffan, J. J., Carroll, J. L., Williams, B. J., & Cardelli, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0109 · Cited by 118

Epithelial‐mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4‐ALK translocation

Kim, H. R., Kim, W. S., Choi, Y. J., Choi, C., Rho, J. K., & Lee, J. C. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.001 · Cited by 114

Epithelial–mesenchymal plasticity and circulating tumor cells: Travel companions to metastases

Francart, M., Lambert, J., Vanwynsberghe, A. M., Thompson, E. W., Bourcy, M., Polette, M., & Gilles, C. (2017) · Developmental Dynamics · doi:10.1002/dvdy.24506 · Cited by 118

Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer

Findlay, V. J., Wang, C., Watson, D. K., & Camp, E. R. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.15 · Cited by 114

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights

Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 119

Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers

Guix, M., Granja, N. D. M., Meszoely, I. M., Adkins, T. B., Wieman, B. M., Frierson, K. E., Sanchez, V., Sanders, M. E., Grau, A. M., Mayer, I. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5939 · Cited by 111

Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer

Kim, H.-P., Han, S.-W., Song, S., Jeong, E.-G., Lee, M.-Y., Hwang, D., Im, S., Bang, Y.-J., & Kim, T.-Y. (2013) · Oncogene · doi:10.1038/onc.2013.285 · Cited by 110

Matrix Metalloproteinase Induction of Rac1b, a Key Effector of Lung Cancer Progression

Stallings‐Mann, M. L., Waldmann, J., Zhang, Y., Miller, E. E., Gauthier, M. L., Visscher, D. W., Downey, G. P., Radisky, E. S., Fields, A. P., & Radisky, D. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004062 · Cited by 110

The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

Jakobsen, K. R., Demuth, C., Sørensen, B. S., & Nielsen, A. L. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.04.07 · Cited by 112

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

Black, P. C., Brown, G. A., Inamoto, T., Shrader, M., Arora, A., Siefker-Radtke, A. O., Adam, L., Theodorescu, D., Wu, X., Munsell, M. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1593 · Cited by 109

Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance

Sung, S., Hsieh, C., Wu, D., Chung, L. W. K., & Johnstone, P. A. S. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2006.12.002 · Cited by 106

Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance

Boeckx, C., Baay, M. F. D., Wouters, A., Specenier, P. M., Vermorken, J. B., Peeters, M., & Lardon, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0013 · Cited by 110

Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype

Zhou, C., Nitschke, A., Xiong, W., Zhang, Q., Tang, Y., Bloch, M., Elliott, S. G., Zhu, Y., Bazzone, L. E., Yu, D. C., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2210 · Cited by 105

Building a better understanding of the intracellular tyrosine kinase PTK6 — BRK by BRK

Brauer, P. M., & Tyner, A. L. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.02.003 · Cited by 105

Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo

Xie, M., He, C.-S., Wei, S., & Zhang, L. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.007 · Cited by 107

The Promise of Multi-Omics and Clinical Data Integration to Identify and Target Personalized Healthcare Approaches in Autism Spectrum Disorders

Higdon, R., Earl, R. K., Stanberry, L. I., Hudac, C. M., Montague, E., Stewart, E., Janko, I., Choiniere, J., Broomall, W., Kolker, N., et al. (2015) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2015.0020 · Cited by 107

DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors

Hoang, P. H., & Landi, M. T. (2022) · Cancers · doi:10.3390/cancers14040961 · Cited by 105

Src as a potential therapeutic target in non-small-cell lung cancer

Giaccone, G., & Zucali, P. A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn048 · Cited by 99

The evolving genomic classification of lung cancer

Shames, D. S., & Wistuba, I. I. (2013) · The Journal of Pathology · doi:10.1002/path.4275 · Cited by 108

Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma

Jung, A. R., Jung, C., Noh, J. K., Lee, Y. C., & Eun, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-60707-x · Cited by 107

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Yoshida, T., Song, L., Bai, Y., Kinose, F., Li, J., Ohaegbulam, K. C., Muñoz-Antonia, T., Qu, X., Eschrich, S. A., Uramoto, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147344 · Cited by 96

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

Cenik, B. K., Ostapoff, K. T., Gerber, D. E., & Brekken, R. A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0995 · Cited by 94

Emerging evidence of epithelial‐to‐mesenchymal transition in lung carcinogenesis

Sato, M., Shames, D. S., & Hasegawa, Y. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02173.x · Cited by 96

p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression

Soto, E., Yanagisawa, M., Marlow, L. A., Copland, J. A., Perez, E. A., & Anastasiadis, P. Z. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200805113 · Cited by 97

Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update

Gurzu, S. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i5.393 · Cited by 97

New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression

Bhatia, S., Wang, P., Toh, A. K. L., & Thompson, E. W. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00071 · Cited by 99

The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer

Zhang, Y., Zeng, Y., Liu, T., Du, W., Zhu, J., Liu, Z., & Huang, J. (2019) · Respiratory Research · doi:10.1186/s12931-019-1137-4 · Cited by 92

Protein Signature of Lung Cancer Tissues

Mehan, M. R., Ayers, D. G., Thirstrup, D. J., Xiong, W., Ostroff, R. M., Brody, E. N., Walker, J. J., Gold, L., Jarvis, T. C., Janjić, N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035157 · Cited by 92

Epithelial Mesenchymal Transition in Aggressive Lung Cancers

Mittal, V. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_3 · Cited by 93

Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway

Rosell, R., Tarón, M., Reguart, N., Isla, D., & Morán, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0627 · Cited by 92

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

Vázquez‐Martín, A., Cufí, S., Oliveras‐Ferraros, C., Torres-Garcia, V. Z., Corominas-Faja, B., Cuyàs, E., Bonavia, R., Visa, J., Martı́n-Castillo, B., Barrajón‐Catalán, E., et al. (2013) · Scientific Reports · doi:10.1038/srep02560 · Cited by 93

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

Giaccone, G., & Wang, Y. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.01.003 · Cited by 94

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

Zucali, P. A., Ruiz, M. I. G., Giovannetti, E., Destro, A., Varella‐Garcia, M., Floor, K., Ceresoli, G. L., Rodríguez, J. A., Garassino, I. M. G., Comoglio, P. M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn240 · Cited by 89

Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2

Somarelli, J. A., Shetler, S., Jolly, M. K., Wang, X., DeWitt, S. B., Hish, A. J., Gilja, S., Eward, W. C., Ware, K. E., Levine, H., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00373-16 · Cited by 88

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy

Yuan, Y. J., Adam, A., Zhao, C., & Chen, H. (2021) · Cancers · doi:10.3390/cancers13040663 · Cited by 87

A comparison of epithelial-to-mesenchymal transition and re-epithelialization

Leopold, P. L., Vincent, J., & Wang, H. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.07.003 · Cited by 93

Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression

Schaefer, G., Shao, L., Tótpál, K., & Akita, R. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3493 · Cited by 87

DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer

Kim, W., Holcomb, T., Januario, T., Du, P., Evangelista, M., Kartha, N., Iniguez, L. A., Soriano, R. H., Huw, L. Y., Stern, H. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2635-t · Cited by 86

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer

Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00281 · Cited by 82

Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs

Mink, S. R., Vashistha, S., Zhang, W., Hodge, A., Agus, D. B., & Jain, A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0460 · Cited by 89

The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis

Heinrich, E. L., Walser, T. C., Krysan, K., Liclican, E. L., Grant, J. L., Rodriguez, N., & Dubinett, S. M. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0089-0 · Cited by 87

Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer

Zhou, J., Wang, J., Zeng, Y., Zhang, X., Hu, Q., Zheng, J., Chen, B., Xie, B., & Zhang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6293 · Cited by 82

Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618

Xiao, Y., Elkins, K., Durieux, J., Lee, L. B., Oeh, J., Yang, L., Liang, X., DelNagro, C., Tremayne, J. R., Kwong, M., et al. (2013) · Neoplasia · doi:10.1593/neo.131304 · Cited by 81

Tumour-microenvironmental interactions: paths to progression and targets for treatment

Box, C., Rogers, S. J., Mendiola, M., & Eccles, S. A. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.06.004 · Cited by 83

Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting

Koppikar, P., Lui, V. W. Y., Man, D., Xi, S., Chai, R. L., Nelson, E. G., Tobey, A. B. J., & Grandis, J. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1328 · Cited by 82

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Lin, L., & Bivona, T. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817297 · Cited by 85

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells

Nishijima, N., Seike, M., Soeno, C., Chiba, M., Miyanaga, A., Noro, R., Sugano, T., Matsumoto, M., Kubota, K., & Gemma, A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3331 · Cited by 82

Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Upregulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells

Mateen, S., Raina, K., Agarwal, C., Chan, D. C. F., & Agarwal, R. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203471 · Cited by 81

Role of Transforming Growth Factor-β In Cancer Progression

Galliher, A. J., Neil, J. R., & Schiemann, W. P. (2006) · Future Oncology · doi:10.2217/14796694.2.6.743 · Cited by 80

Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition

Ibrahim, R., Matsubara, D., Osman, W. M., Morikawa, T., Goto, A., Morita, S., Ishikawa, S., Aburatani, H., Takai, D., Nakajima, J., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.02.013 · Cited by 80

Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines

Haddad, Y., Choi, W., & McConkey, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1733 · Cited by 80

A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT

Bryant, J. L., Britson, J. S., Balko, J. M., Willian, M. C., Timmons, R. B., Frolov, A., & Black, E. P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.465 · Cited by 80

Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer

Legras, A., Pécuchet, N., Imbeaud, S., Pallier, K., Didelot, A., Roussel, H., Gibault, L., Fabre, E., Pimpec‐Barthes, F. L., Laurent‐Puig, P., et al. (2017) · Cancers · doi:10.3390/cancers9080101 · Cited by 82

Stem cell-like ALDH bright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin

Corominas-Faja, B., Oliveras‐Ferraros, C., Cuyàs, E., Segura‐Carretero, A., Joven, J., Martı́n-Castillo, B., Barrajón‐Catalán, E., Micol, V., Bosch‐Barrera, J., & Menéndez, J. A. (2013) · Cell Cycle · doi:10.4161/cc.26417 · Cited by 80

Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition

Hwang, W., Chiu, Y.-F., Kuo, M.-H., Lee, K.-L., Lee, A.-C., Yu, C.-C., Chang, J.-L., Huang, W.-C., Hsiao, S.-H., Lin, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3168 · Cited by 78

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

Cufí, S., Bonavia, R., Vázquez‐Martín, A., Oliveras‐Ferraros, C., Corominas-Faja, B., Cuyàs, E., Martı́n-Castillo, B., Barrajón‐Catalán, E., Visa, J., Segura‐Carretero, A., et al. (2013) · Scientific Reports · doi:10.1038/srep02459 · Cited by 83

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation

Monica, S. L., Madeddu, D., Tiseo, M., Vivo, V., Galetti, M., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Falco, A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.006 · Cited by 75

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer

Lee, W.-C., Diao, L., Wang, J., Zhang, J., Roarty, E. B., Varghese, S., Chow, C.-W. B., Fujimoto, J., Behrens, C., Cascone, T., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0029-3 · Cited by 73

Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency

Hu, S., Fu, W., Li, T., Yuan, Q., Wang, F., Lv, G., Lv, Y., Fan, X., Shen, Y., Lin, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0339 · Cited by 72

Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines

Bai, X., Zhang, X., Yang, S., An, S., Chen, Z., Su, J., Xie, Z., Gou, L.-Y., & Wu, Y.-L. L. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149370 · Cited by 72

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

Morgillo, F., Bareschino, M. A., Bianco, R., Tortora, G., & Ciardiello, F. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00200.x · Cited by 75

Predicting the outcome of chemotherapy for lung cancer

Rosell, R., Cecere, F. L., Santarpía, M., Reguart, N., & Tarón, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.011 · Cited by 73

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance

Zhang, X., Maity, T. K., ROSS, K. E., Qi, Y. A., Cultraro, C. M., Bahta, M., Pitts, S. C., Keswani, M., Gao, S., Nguyen, K. D. P., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2435 · Cited by 72

Cigarette smoke extract stimulates epithelial–mesenchymal transition through Src activation

Zhang, H., Liu, H., Borok, Z., Davies, K. J. A., Ursini, F., & Forman, H. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.01.024 · Cited by 74

The biological and clinical importance of epithelial–mesenchymal transition in circulating tumor cells

Liu, H., Zhang, X., Li, J., Sun, B., Qian, H., & Yin, Z. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1752-x · Cited by 75

Drug-biomarker co-development in oncology – 20 years and counting

Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 75

SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells

Ozawa, H., Ranaweera, R. S., Izumchenko, E., Makarev, E., Zhavoronkov, A. A., Fertig, E. J., Howard, J. D., Marković, A. K., Bedi, A., Ravi, R. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1686 · Cited by 72

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors

Balko, J. M., Potti, A., Saunders, C. P., Stromberg, A. J., Haura, E. B., & Black, E. P. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-289 · Cited by 71

Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring

Bhatia, S., Monkman, J. H., Toh, A. K. L., Nagaraj, S. H., & Thompson, E. W. (2017) · Biochemical Journal · doi:10.1042/bcj20160782 · Cited by 76

Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines

Pino, M. S., Balsamo, M., Modugno, F. D., Mottolese, M., Alessio, M., Melucci, E., Milella, M., McConkey, D. J., Philippar, U., Gertler, F. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0436 · Cited by 70

Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity

Rosanò, L., Castro, V. D., Spinella, F., Tortora, G., Nicotra, M. R., Natali, P. G., & Bagnato, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0883 · Cited by 70

DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties

Little, A. C., Sham, D., Hristova, M., Danyal, K., Heppner, D. E., Bauer, R., Sipsey, L., Habibovic, A., & van der Vliet, A. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.61 · Cited by 70

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

Thomson, S., Buck, E. A., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N. W., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Thomson, S., Petti, F., Sujka-Kwok, I., Buck, E. A., Barr, S. M., Miglarese, M. R., & Haley, J. D. (2007) · Molecular Cancer Therapeutics

Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

Argast, G. M., Bean, J. M., Wang, J., O'Connor, M., Feng, B., Nicoletti, R., Lerner, L. R., Heyer, J., Chiu, M. I., Robinson, M. O., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5063

Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.

Pool, M. D., Fidler, M. J., Basu, S., Mahon, B., Buckingham, L. E., Walters, K. K., Batus, M., Hensing, T. A., Borgia, J. A., & Bonomi, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e19117

P3-015: Clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer

Zhou, C., Deng, Q., & Su, C. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283501.96516.b4